Literature DB >> 16569642

An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility.

George K Wang1, Limei Hu, Gregory N Fuller, Wei Zhang.   

Abstract

In the study we report here, we tested the hypothesis that insulin-like growth factor-binding protein 2 (IGFBP2) promotes cell mobility through its interaction with integrin alpha5. Our previous microarray studies showed that IGFBP2 activates the expression of integrin alpha5. In addition, IGFBP2 has an Arg-Gly-Asp (RGD) domain, which is a known integrin binding motif. We first confirmed our microarray results by showing that the expression of integrin alpha5 is indeed up-regulated at the protein level in IGFBP2-overexpressing SNB19 glioma cells. Using co-immunoprecipitation, we confirmed that IGFBP2 does interact with integrin alpha5. To confirm that IGFBP2 interacts directly with integrin alpha5 through the RGD domain, we created an RGD --> RGE mutant (D306E) IGFBP2 and stably overexpressed the mutant IGFBP2 in the same cell line. Co-immunoprecipitation then showed that D306E-IGFBP2 had no detectable binding with integrin alpha5. We further observed that IGFBP2-overexpressing cells have extensive cell surface lamellipodia, whereas D306E-IGFBP2-overexpressing cells show abundant cell surface focal adhesions. Consistent with this, phenotype analysis then showed that IGFBP2-overexpressing cells have elevated migration rates compared with vector control; in contrast, the migration rates of the D306E-IGFBP2-overexpressing cells were not elevated and were comparable with that of vector control. Decreased expression of integrin alpha5 by small interference RNA in IGFBP2-overexpressing cells also reduced cell mobility. Therefore, we have concluded that one mechanism by which IGFBP2 activates IGFBP2-induced cell mobility is through its interaction with integrin alpha5 and this interaction is specifically mediated through the RGD domain on IGFBP2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16569642     DOI: 10.1074/jbc.M513686200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

Review 1.  The insulin-like growth factor system in cancer.

Authors:  S John Weroha; Paul Haluska
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

2.  Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network.

Authors:  Kristen M Holmes; Matti Annala; Corrine Y X Chua; Sarah M Dunlap; Yuexin Liu; Niek Hugen; Lynette M Moore; David Cogdell; Limei Hu; Matti Nykter; Kenneth Hess; Gregory N Fuller; Wei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-15       Impact factor: 11.205

3.  CD44 expression in endothelial colony-forming cells regulates neurovascular trophic effect.

Authors:  Susumu Sakimoto; Valentina Marchetti; Edith Aguilar; Kelsey Lee; Yoshihiko Usui; Salome Murinello; Felicitas Bucher; Jennifer K Trombley; Regis Fallon; Ravenska Wagey; Carrie Peters; Elizabeth L Scheppke; Peter D Westenskow; Martin Friedlander
Journal:  JCI Insight       Date:  2017-01-26

4.  High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma.

Authors:  Lucia Tombolan; Francesca Orso; Vincenza Guzzardo; Silvia Casara; Angelica Zin; Massimo Bonora; Chiara Romualdi; Carlotta Giorgi; Gianni Bisogno; Rita Alaggio; Paolo Pinton; Cristiano De Pittà; Daniela Taverna; Angelo Rosolen; Gerolamo Lanfranchi
Journal:  Am J Pathol       Date:  2011-09-13       Impact factor: 4.307

5.  Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping.

Authors:  Robert J Higgins; Peter J Dickinson; Richard A LeCouteur; Andrew W Bollen; Huamin Wang; Hua Wang; Linda J Corely; Lynnette M Moore; Wei Zang; Gregory N Fuller
Journal:  J Neurooncol       Date:  2009-12-05       Impact factor: 4.130

6.  Crosstalks between integrin alpha 5 and IGF2/IGFBP2 signalling trigger human bone marrow-derived mesenchymal stromal osteogenic differentiation.

Authors:  Zahia Hamidouche; Olivia Fromigué; Jochen Ringe; Thomas Häupl; Pierre J Marie
Journal:  BMC Cell Biol       Date:  2010-06-23       Impact factor: 4.241

7.  Cloning, molecular characterization and expression analysis of insulin-like growth factor binding protein-2 (IGFBP-2) cDNA in goldfish, Carassius auratus.

Authors:  Wenbo Chen; Weiguo Li; Zhen Zhang; Xiaoxue Jiang; Mengjie Li
Journal:  Fish Physiol Biochem       Date:  2014-07-04       Impact factor: 2.794

8.  PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions.

Authors:  Kenichi Miyako; Laura J Cobb; Malik Francis; Alden Huang; Bonnie Peng; John E Pintar; Hiroyoshi Ariga; Pinchas Cohen
Journal:  Mol Endocrinol       Date:  2008-12-18

9.  Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies.

Authors:  Lynette M Phillips; Xinhui Zhou; David E Cogdell; Corrine Yingxuan Chua; Anouk Huisinga; Kenneth R Hess; Gregory N Fuller; Wei Zhang
Journal:  J Pathol       Date:  2016-06-10       Impact factor: 7.996

10.  Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.

Authors:  G E Konecny; R Glas; J Dering; K Manivong; J Qi; R S Finn; G R Yang; K-L Hong; C Ginther; B Winterhoff; G Gao; J Brugge; D J Slamon
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.